Clinical trial · Interventional
Meditation and Cognitive Function in Women With Breast Cancer
Feasibility Study of Meditation, Cognitive Function, and Quality of Life in Women With Breast Cancer
NCT00556218CI-TRIAL-00060600completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this behavioral research study is to learn if participating in a Tibetan meditation program helps to improve quality of life for women after chemotherapy and during recovery from breast cancer. Whether the meditation program helps to improve brain function and sleep quality will also be studied.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No Meditation | Behavioral | — | UNRESOLVED |
| Tibetan Meditation Program | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Tibetan Meditation
- interventionNames
- Behavioral: Tibetan Meditation Program
- type
- OTHER
- label
- No Meditation
- interventionNames
- Behavioral: No Meditation
Primary outcomes (2)
- measure
- Number of Eligible Women Approached Who Consented to be in Trial (Feasibility)
- timeFrame
- 2 Years
- measure
- Women's Reported Satisfaction with Tibetan Meditation intervention
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Women with stage I - III breast cancer who have undergone chemotherapy (either neoadjuvant or adjuvant) 6 - 60 months prior to recruitment. 2. Women who report cognitive impairment since starting chemotherapy as assessed by four questions from the FACT-Cog. 3. Women must be 18 years or older. 4. Women must be able to read, write and speak English. 5. Women must be currently undergoing hormone therapy (e.g., Tamoxifen or AIs) 6. Willing to come to MDACC for the meditation sessions and assessment sessions. 7. Women must be within 2 hours driving distance of MDACC. Exclusion Criteria: 1. Women who have a documented diagnosis of a formal thought disorder (e.g., schizophrenia) will be excluded from the study. 2. Women with metastatic disease to the brain or any past neurologic injury. 3. Women with a Mini-Mental State Examination score of 23 or below. 4. Women with recurrent cancer
References
Publications (0)
Data not yet available
No reference posted for this study.